Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Langenau – page 4

649 clinical trials in Langenau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Langenau at a glance
649
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

649 trials in Langenau

Open in trial search

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Dr. Falk Pharma GmbH

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Desloratadine
  • Sponsor:Allergy Therapeutics (UK) Limited

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant
  • Sponsor:Corcept Therapeutics Inc.

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Phase 1 Study of JNJ-95804306 in Adults with Relapsed or Refractory AML, Higher‑Risk MDS, CLL and SLL

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Janssen Cilag International

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Surlorian
  • Sponsor:Armgo Pharma Inc.

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Langenau

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical research focusing on plaque psoriasis and psoriatic arthritis, evaluating novel therapeutic approaches for both biologic-naive and experienced patients. Studies aim to assess treatment efficacy in reducing disease symptoms and improving patient outcomes.

  • Moderate to Severe Plaque Psoriasis
  • Active Psoriatic Arthritis
  • Long-term Safety Studies

Multiple investigations are comparing new therapeutic agents against placebo and established treatments.

02 Chronic Skin Disorders

Comprehensive studies addressing hidradenitis suppurativa and atopic dermatitis. Research focuses on evaluating new treatments for these challenging conditions, with emphasis on both immediate efficacy and long-term management.

  • Hidradenitis Suppurativa Management
  • Atopic Dermatitis Treatments
  • Novel Therapeutic Approaches

Trials are examining both topical and systemic treatments for optimal disease control.

03 Dermatological Conditions

Innovative research addressing various skin conditions including chronic venous ulcers, actinic keratosis, and rosacea. Studies range from stem cell therapies for wound healing to novel topical treatments.

  • Wound Healing Therapies
  • Skin Lesion Treatments
  • Inflammatory Conditions

Research includes both traditional and cutting-edge therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.